Magnolia Capital Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Magnolia Capital Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$545K	Hold	77,405	–	–	0.09%	198
2026 Q1	$524K	Hold	77,405	–	–	0.1%	199
2025 Q4	$616K	Buy	77,405 +67,405	+674%	+$504K	0.13%	155
2025 Q3	$68.7K	Hold	10,000	–	–	0.02%	232
2025 Q2	$39K	Hold	10,000	–	–	0.01%	240
2025 Q1	$37.9K	Sell	10,000 -160	-2%	-$915	0.01%	225
2024 Q4	$55.2K	Buy	10,160 +160	+2%	+$755	0.01%	228
2024 Q3	$41.9K	Hold	10,000	–	–	0.02%	140
2024 Q2	$29.5K	Buy	+10,000	New	+$27.4K	0.02%	121

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Magnolia Capital Advisors's DMAC Position: Q2 2026 in Review

Magnolia Capital Advisors held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 77,405 shares worth $545K. The position accounts for 0.09% of the portfolio, ranked #198.

Magnolia Capital Advisors first reported a position in DMAC in Q2 2024 and has held it in 9 quarters since. The position peaked at $616K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Magnolia Capital Advisors held 77,405 shares of DiaMedica Therapeutics worth $545K as of Q2 2026.
Magnolia Capital Advisors left its DiaMedica Therapeutics share count unchanged in Q2 2026.
DiaMedica Therapeutics made up 0.09% of Magnolia Capital Advisors's portfolio in Q2 2026, its #198 holding.
Magnolia Capital Advisors first reported a position in DiaMedica Therapeutics in Q2 2024 and has held it in 9 quarters since.
Magnolia Capital Advisors's DiaMedica Therapeutics position peaked at $616K in Q4 2025.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Magnolia Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.